Category: Mergers & AcquisitionsSyndicate content

EQT frontrunner for Siemens hearing-aids business: sources

October 22, 2014 by MassDevice

Siemens is in advanced talks to sell its hearing-aids business to private equity shop EQT, unnamed sources tell Reuters.

EQT frontrunner for Siemens hearing-aids business: sources

Sorin drops $20m on stake in Respicardia

October 22, 2014 by Alexander Soule

Sorin Group drops $20 million on a stake in Minnetonka, Minn.-based Respicardia, which is developing implantable devices to treat central sleep apnea.

Sorin drops $20m on stake in Respicardia

Sorin Group (BIT:SRN) said it invested $20 million in a minority stake and controlling option in Minnetonka, Minn.-based Respicardia, which is developing implantable devices to treat central sleep apnea.

Abbott to go ahead with $5.3B Mylan deal, says 3rd-quarter sales match forecasts

October 22, 2014 by MassDevice

Abbott says it will go ahead with its plan to deal its generic pharmaceuticals line to Mylan for $5.3 billion and reports 3rd-quarter sales in line with expectations.

Abbott to go ahead with $5.3B Mylan deal, says 3rd-quarter sales match forecasts

Covidien, Medtronic shares jump on affirmation of $43B merger

October 22, 2014 by Brad Perriello

Shares of Medtronic and Covidien gain after Medtronic affirms its $43 billion acquisition plans, saying it now expects to close the deal for Covidien late this year or early in 2015.

Covidien, Medtronic shares jump on affirmation of $43B merger

JNJ/Synthes integration continues to bring hefty charges | The week in medtech M&A

October 22, 2014 by MassDevice

Here's a look at some of the top regulatory stories for medical device companies this week: JNJ continues to pay hefty integration charges on Synthes deal; Stryker: Mako sales not as strong as we hoped; ConvaTec owners appoint banks to explore sale: sources; BD buys Irish next-gen sequencing startup GenCell Biosystems; Valeant says may raise Allergan bid; beats on profit

JNJ continues to pay hefty integration charges on Synthes deal

October 16, 2014 by Brian Johnson

Allergan says it stands by statements on Valeant

October 21, 2014 by MassDevice

Allergan says there's no evidence to back claims by hostile suitors Valeant Pharmaceuticals and hedge mogul William Ackman's Pershing Square Capital Management that Allergan CEO David Pyott led a smear campaign against them.

Allergan says it stands by statements on Valeant

Valeant says may raise Allergan bid; beats on profit

October 20, 2014 by MassDevice

Valeant Pharmaceuticals says it might up the ante in its hostile takeover bid for Allergan as it reports higher-than-forecast profits for its 3rd quarter.

Valeant says may raise Allergan bid; beats on profit
Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp